Literature DB >> 2530586

Wild-type p53 can inhibit oncogene-mediated focus formation.

D Eliyahu1, D Michalovitz, S Eliyahu, O Pinhasi-Kimhi, M Oren.   

Abstract

Mutant forms of the p53 cellular tumor antigen elicit neoplastic transformation in vitro. Recent evidence indicated that loss of normal p53 expression is a frequent event in certain types of tumors, raising the possibility that such loss provides transformed cells with a selective growth advantage. Thus, it was conceivable that the mutants might contribute to transformation by abrogating normal p53 function. We therefore studied the effect of plasmids encoding wild-type (wt) p53 on the ability of primary rat embryo fibroblasts to be transformed by a combination of mutant p53 and ras. It was found that wt p53 plasmids indeed caused a marked reduction in the number of transformed foci. Furthermore, wt p53 plasmids also suppressed the induction of transformed foci by combinations of bona fide oncogenes, such as myc plus ras or adenovirus E1A plus ras. On the other hand, plasmids carrying mutations in the p53 coding region totally failed to inhibit oncogene-mediated focus induction and often even slightly stimulated it. Hence, such mutations completely abolished the activity of wt p53 that is responsible for the "suppressor" effect. The latter fact is of special interest, since similar mutations in p53 are often observed in human and rodent tumors. The inhibitory effect of p53 was most pronounced when early-passage cells were used as targets, whereas established cell lines were less sensitive. These data support the notions that wt p53 expression may be restrictive to neoplastic progression and that p53 inactivation may play a crucial role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530586      PMCID: PMC298370          DOI: 10.1073/pnas.86.22.8763

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells.

Authors:  W E Mercer; D Nelson; A B DeLeo; L J Old; R Baserga
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

2.  Isolation of a transforming sequence from a human bladder carcinoma cell line.

Authors:  C Shih; R A Weinberg
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

Review 3.  The 53,000-dalton cellular protein and its role in transformation.

Authors:  L Crawford
Journal:  Int Rev Exp Pathol       Date:  1983

4.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

5.  Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture.

Authors:  H E Ruley
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

6.  Allelotype of colorectal carcinomas.

Authors:  B Vogelstein; E R Fearon; S E Kern; S R Hamilton; A C Preisinger; Y Nakamura; R White
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

7.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

Authors:  D Wolf; N Harris; V Rotter
Journal:  Cell       Date:  1984-08       Impact factor: 41.582

8.  In vivo identification of the transforming gene product of simian sarcoma virus.

Authors:  K C Robbins; S G Devare; E P Reddy; S A Aaronson
Journal:  Science       Date:  1982-12-10       Impact factor: 47.728

9.  A single gene and a pseudogene for the cellular tumour antigen p53.

Authors:  R Zakut-Houri; M Oren; B Bienz; V Lavie; S Hazum; D Givol
Journal:  Nature       Date:  1983 Dec 8-14       Impact factor: 49.962

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  213 in total

1.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

2.  Regulation of Cdc42-mediated morphological effects: a novel function for p53.

Authors:  Gilles Gadéa; Laure Lapasset; Cécile Gauthier-Rouvière; Pierre Roux
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

3.  Growth inhibition of human glioma cells by transfection-induced P21 and its effects on telomerase activity.

Authors:  K Harada; K Kurisu; T Sadatomo; H Tahara; E Tahara; T Ide; E Tahara
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

4.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 5.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

Review 6.  The involvement of oncogenes and tumor suppressor genes in the control of apoptosis.

Authors:  M Oren
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

7.  Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase.

Authors:  D Lin; M T Shields; S J Ullrich; E Appella; W E Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

9.  Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.

Authors:  D M Milne; R H Palmer; D W Meek
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

Review 10.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.